戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ith tryptase in estimating the need for bone marrow biopsy.
2 mastocytosis) and thus candidates for a bone marrow biopsy.
3  aggregates, and atypical mast cells on bone marrow biopsy.
4 94% and 100% for PET-CT and 40% and 100% for marrow biopsy.
5 ent accuracy to replace routine staging bone marrow biopsy.
6 e to up to 31 drugs within 5 days after bone marrow biopsy.
7 e of biopsy site than the usual random iliac marrow biopsy.
8 ne and serum immunoelectrophoresis, and bone marrow biopsy.
9 diagnosis usually depends on results of bone marrow biopsy.
10 the potential to reduce the need for staging marrow biopsy.
11 re red cell aplasia (PRCA) confirmed by bone marrow biopsy.
12  with hematologic response criteria and bone marrow biopsies.
13 ot density compared with normal control bone marrow biopsies.
14  relevance of expression in 55 archival bone marrow biopsies.
15 loid leukemia (AML) routinely undergo a bone marrow biopsy 7-10 days after induction chemotherapy to
16                             Analysis of bone marrow biopsies after CTL019 revealed 8 patients with pe
17 Response was assessed by weekly CBC and bone marrow biopsy after cycle 2 and after each subsequent cy
18                                         Bone marrow biopsy analysis showed 5% plasma cells, which sta
19 tochemically by factor VIII staining of bone marrow biopsies and quantified by assessment of microves
20 s of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothelial g
21               Five patients were upstaged by marrow biopsy and 7 by contrast-enhanced CT in the bowel
22                           The patient's bone marrow biopsy and aspirate displayed unique pathologic f
23 and negligible gene marking, diagnostic bone marrow biopsy and aspirate were performed at day 88.
24                                       A bone marrow biopsy and aspiration revealed a mildly hypercell
25  myeloma was diagnosed and confirmed by bone marrow biopsy and aspiration.
26                      Congo red stain on bone marrow biopsy and fat pad aspirate was negative for amyl
27  ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac
28  ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac
29 up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical and histochemical
30 is, in the selection of those needing a bone marrow biopsy, and in the documentation of disease progr
31 2005 had data extracted from staging PET-CT, marrow biopsy, and treatment records.
32 o identify those patients who require a bone marrow biopsy, and whether the pathogenesis of IA involv
33 suspicious lymphocytic infiltrates in a bone marrow biopsy as the sole suggestion of residual disease
34 adioimmunotherapy, after lymph node and bone marrow biopsies at 2-4 and/or 19 h after injection.
35 he diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according to m
36 etastatic CRPC who underwent transiliac bone marrow biopsy between October 2007 and March 2010.
37 ll lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marrow inv
38                                Skin and bone marrow biopsies can thus be used to generate de novo fun
39   A percutaneous biopsy of the mass and bone marrow biopsy confirmed the diagnosis of primary adrenal
40 rum paraproteins and/or light chains or bone marrow biopsy defined response.
41 inal mass was discovered, and tumor and bone marrow biopsies disclosed rhabdomyosarcoma.
42 ide therapy should undergo surveillance bone marrow biopsy every 2 to 3 years and that those who show
43                                         Bone marrow biopsy exhibited mostly mixed patterns of small B
44 icaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggregates
45 ed at the protein level by immunostaining of marrow biopsies for NY-ESO-1.
46 esis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients.
47                            We evaluated bone marrow biopsies from 40 children with newly diagnosed, u
48 n factor (MITF), is highly expressed in bone marrow biopsies from 9 of 10 patients with systemic mast
49                           Evaluation of bone marrow biopsies from myeloma patients revealed a strong
50                   Moreover, analysis of bone marrow biopsies from myeloma patients reveals a positive
51                                      In bone marrow biopsies from patients with DBA or del(5q) myelod
52 taneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokin
53 tochemical paraffin section staining of bone marrow biopsies in the staging of B-cell malignant lymph
54                                Although bone marrow biopsies in these patients showed increased numbe
55 imal test indicating the necessity of a bone marrow biopsy in ISM-suspected patients.
56 only used test to estimate the need for bone marrow biopsy in patients suspected to have indolent sys
57 r DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogeneity
58 ected by immunohistochemistry in normal bone marrow biopsies, indicating an in vivo function.
59  response to therapy; also, the role of bone marrow biopsy is being revisited.
60                                       A bone marrow biopsy is no longer indicated for the routine sta
61                                         Bone marrow biopsies largely replaced by PCa were analyzed us
62                                         Bone marrow biopsy may reveal hemophagocytosis and marrow his
63 se activity in the plasma isolated from bone marrow biopsies of 100 patients reveals 86 positive for
64 dominant clonotypes in blood and in historic marrow biopsies of 35 AA, 37 MDS, and 21 paroxysmal noct
65 quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilitate i
66  cutoff correctly classifies diagnostic bone marrow biopsies of MPN,U patients specified upon follow-
67                  In this investigation, bone marrow biopsies of the anterior iliac crest were examine
68              Responses were assessed by bone marrow biopsy on day 15 of the first course and by clini
69  features with the exception that their bone marrow biopsy pathology revealed abundant neutrophils co
70                                         Bone marrow biopsy performed in two of these five patients sh
71 Cr corresponded with the high degree of bone marrow biopsies positive for atypical mast cells, the pr
72 aged using clinical assessment, CT, and bone marrow biopsy (RATHL stage).
73                                         Bone marrow biopsy revealed hypercellular marrow.
74                                         Bone marrow biopsy revealed no evidence of infectious or neop
75                  MAC loads in bilateral bone marrow biopsy samples from 7 subjects were highly correl
76                          Early in treatment, marrow biopsies showed increased megakaryocyte number an
77                                  Serial bone marrow biopsies showed normalization of trilineage hemat
78                         Comparison with bone marrow biopsies showed that FDG-PET was not reliable for
79                                         Bone marrow biopsy showed 60% infiltration with lambda light
80                 Immunohistochemistry of bone marrow biopsy showed an increased number of plasma cells
81                            In 3 patients the marrow biopsy specimen was positive but the PET scan nor
82        After histologic analysis of the bone marrow biopsy specimen, diagnosis of Waldenstrom macrogl
83                          In this study, bone marrow biopsy specimens from 36 patients with T-cell GLL
84  TMA was constructed using pretreatment bone marrow biopsy specimens from 64 adult patients with ALL.
85 e were detected on peripheral smear and bone marrow biopsy specimens, and PCR amplified Ehrlichia ewi
86 gs, and immunohistochemical staining of bone marrow biopsy specimens.
87                             Analysis of bone marrow-biopsy specimens obtained from two patients at th
88         Immunohistochemical analysis of bone marrow-biopsy specimens showed that only myeloma cells c
89                 These data suggest that bone marrow biopsy using antigen-targeted magnetic nanopartic
90                                         Bone marrow biopsy was done on day -7 to estimate radiation d
91  nondiagnostic, and lumbar puncture and bone marrow biopsies were negative.
92                       With informed consent, marrow biopsies were obtained to collect prostate tumor.
93                 One hundred eighty-four bone marrow biopsies were obtained, and 48 had prostate tumor
94                  Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer pati
95 GFR-expressing tumor declined on serial bone marrow biopsies with combination therapy alone.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。